Folate vs methylfolate and MTHFR variants: what genetic testing companies don't tell you

Direct-to-consumer genetic reports almost universally flag the MTHFR C677T and A1298C variants as actionable, recommending the active 5-methyltetrahydrofolate (5-MTHF) form of folate. The clinical genetics community has spent the last decade walking that recommendation back. Here is what the actual literature shows about the differences between folic acid, food folate, and methylfolate — and where the MTHFR genotype actually matters.

What MTHFR does — and what its common variants do

Methylenetetrahydrofolate reductase converts 5,10-methyleneTHF to 5-MTHF, the active circulating folate that donates a methyl group to homocysteine remethylation. The C677T (rs1801133) variant produces a thermolabile enzyme with reduced activity at body temperature. Heterozygotes (about 40 percent of populations of European descent) retain roughly 65 percent of wild-type activity; homozygotes have roughly 30 percent activity. The A1298C variant has a smaller effect on enzyme kinetics. The 2023 American College of Medical Genetics practice resource explicitly stated that MTHFR variant testing is not indicated outside hyperhomocysteinemia workups and that broad clinical conclusions about supplementation should not be drawn from the genotype (PMID: 36795577).¹

Folic acid, 5-MTHF, and folinic acid: practical equivalences

Folic acid is the synthetic monoglutamate used in food fortification. It is converted to dihydrofolate and then THF by dihydrofolate reductase. At habitual supplemental doses (≤400 mcg), this conversion is essentially complete in most adults. Above 1 mg/day, unmetabolised folic acid accumulates in plasma, a phenomenon associated with theoretical concerns about masking B12 deficiency and altered immune signalling (PMID: 19153162).² 5-MTHF (the form sold as Metafolin or Quatrefolic) bypasses MTHFR but enters the same downstream pool. A 2014 head-to-head bioavailability trial in homozygous C677T women found similar steady-state red-cell folate after 24 weeks of folic acid 400 mcg/day or equivalent 5-MTHF (PMID: 24808476).³ Folinic acid (leucovorin) is a distinct intermediate used clinically to rescue methotrexate toxicity and is not interchangeable for routine supplementation.

Where MTHFR genotype matters clinically

Two settings have a defensible evidence base. First, when homocysteine is elevated (>15 µmol/L), determining MTHFR status can inform whether B12-only therapy will suffice. Second, in pregnancy planning for women with prior neural tube defects, the CDC and SOGC recommend 4 mg/day of folic acid pre-conception regardless of MTHFR genotype, because the larger absolute dose overrides genotype-driven differences (PMID: 32826003).⁴ Outside these settings, MTHFR genotype does not alter routine supplementation recommendations. A 2021 European Society of Human Genetics position paper rejected broad MTHFR-based methylfolate prescribing as not evidence-based (PMID: 33772160).⁵

When 5-MTHF actually helps

There are two situations where 5-MTHF specifically is reasonable: methotrexate-treated patients on rheumatology indications who need folate supplementation without interfering with drug action (where folinic acid is the formal recommendation), and patients with documented hyperhomocysteinemia and a homozygous MTHFR variant who are intolerant of high-dose folic acid. A 2023 systematic review found that 5-MTHF at 800 mcg/day lowered homocysteine slightly more than equivalent folic acid in MTHFR 677TT homozygotes, but the absolute difference was clinically modest (PMID: 36720289).⁶

What this means for routine use

For routine prenatal supplementation, 400-800 mcg/day folic acid is the regulatory and CDC default. Methylfolate at equivalent doses is acceptable but not superior except in narrow circumstances. The "MTHFR mutation requires methylfolate" framing that pervades direct-to-consumer reports and social media is not supported by the genetics or clinical-trial literature. Patients with persistent elevated homocysteine on adequate folate intake should be evaluated for B12 deficiency, hypothyroidism, and renal function before assuming MTHFR genotype is the culprit. The 2024 NIH Office of Dietary Supplements folate fact sheet remains the most current consensus reference and recommends folate from food, fortification, and pre-natal supplementation without any MTHFR-genotype caveat (NIH ODS, 2024).⁷